|Other Names||Zinc finger MIZ domain-containing protein 2, PIAS-like protein Zimp7, ZMIZ2, KIAA1886, ZIMP7|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1252a was selected from the C-term region of human PIASz1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Increases ligand-dependent transcriptional activity of AR and other nuclear hormone receptors.|
|Cellular Location||Nucleus. Note=Detected at replication foci throughout S phase|
|Tissue Location||Expressed most abundantly in testis with lower levels in heart, brain, pancreas, prostate and ovary|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
PIASz is a members of the PIAS (protein inhibitor of activated signal transducer and activator of transcription) family of proteins, negative regulators of the Janus family of tyrosine kinase (JAK)-signal transducer and activator of transcription pathway. PIAS proteins have been shown to act as transcriptional co-regulators of multiple signaling pathways in various cellular processes. PIASz increases ligand-dependent transcriptional activity of androgen receptor and other nuclear hormone receptors, possibly through alteration of chromatin structure by SWI/SNF-like BAF complexes.
Muller S, et al., Nat Rev Mol Cell Biol. 2001 2(3):202-10 Review.Hochstrasser M. Cell. 2001 107(1):5-8. Review.Kahyo T, et al., Mol Cell. 2001 Sep;8(3):713-8.Yeh ET, et al., Gene. 2000 May 2;248(1-2):1-14. Review.Keane,M.M., et al., Oncogene 18 (22), 3365-3375 (1999)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.